151. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy
- Author
-
Marco Gambacciani, M. Ciaponi, G. Bevilacqua, Andrea R. Genazzani, Patrizia Monteleone, Caterina Benussi, and Barbara Cappagli
- Subjects
medicine.medical_specialty ,Osteoporosis ,Dydrogesterone ,General Biochemistry, Genetics and Molecular Biology ,Bone remodeling ,Internal medicine ,medicine ,Medroxyprogesterone acetate ,Humans ,Femur ,Prospective Studies ,Osteoporosis, Postmenopausal ,Femoral neck ,Estrogens, Conjugated (USP) ,Trochanter ,Progesterone Congeners ,business.industry ,Estrogen Replacement Therapy ,Obstetrics and Gynecology ,Megestrol ,Middle Aged ,medicine.disease ,Osteopenia ,medicine.anatomical_structure ,Endocrinology ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Objectives: Previous studies indicate that low-dose hormone replacement therapy (LD-HRT) can relieve vasomotor symptoms and prevent spine bone loss. Methods: In the present study, we evaluated the effects of a low dose of conjugated equine estrogens (CEE; 0.3 mg) associated with different progestins in continuous combined scheme [2.5 mg of medroxyprogesterone acetate (n=25), 5 mg dydrogesterone (n=27), 2.5 mg nomegestrol (n=11)] as single group, on femur bone mineral density (BMD) and bone metabolism in young postmenopausal women (≤56 years). All women were supplemented with 1 g of calcium per day, and compared with women treated with 1 g of calcium per day alone (control group, n=15). There were no significant differences in age, body mass index (BMI), hormone values, bone metabolism markers and femur BMD in the treatment and control groups before the study. Results: In calcium-treated women serum plasma osteocalcin (BGP) and hydroxyproline/creatinine urinary excretion (OHP/Cr) remained stable during all the observation period. In this group, femoral neck, Ward's triangle and trochanter BMD showed a progressive and significant (P
- Published
- 2003